Oncogenic <i>PIK3CA</i> mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.

Su YL, Huang SY, Kuo CW, Xiao LY, Lin CT, Chen YH, Chang LC, Kuo MC, Wu CC, Peng JM, Wu CL, Huang HY, Chien CY.

Open source

DOI
10.1136/jitc-2026-014770
Published
2026-07-07
Container
J Immunother Cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2026-014770,
  title = {Oncogenic \<i\>PIK3CA\</i\> mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.},
  author = {Su YL and  Huang SY and  Kuo CW and  Xiao LY and  Lin CT and  Chen YH and  Chang LC and  Kuo MC and  Wu CC and  Peng JM and  Wu CL and  Huang HY and  Chien CY.},
  year = {2026},
  journal = {J Immunother Cancer},
  doi = {10.1136/jitc-2026-014770},
  url = {https://doi.org/10.1136/jitc-2026-014770}
}

RIS

TY  - JOUR
TI  - Oncogenic <i>PIK3CA</i> mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.
AU  - Su YL
AU  -  Huang SY
AU  -  Kuo CW
AU  -  Xiao LY
AU  -  Lin CT
AU  -  Chen YH
AU  -  Chang LC
AU  -  Kuo MC
AU  -  Wu CC
AU  -  Peng JM
AU  -  Wu CL
AU  -  Huang HY
AU  -  Chien CY.
PY  - 2026
JO  - J Immunother Cancer
DO  - 10.1136/jitc-2026-014770
UR  - https://doi.org/10.1136/jitc-2026-014770
ER  - 

APA

YL, S., SY, H., CW, K., LY, X., CT, L., YH, C., LC, C., MC, K., CC, W., JM, P., CL, W., HY, H., & CY., C. (2026). Oncogenic <i>PIK3CA</i> mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.. J Immunother Cancer. https://doi.org/10.1136/jitc-2026-014770

Source records